Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study

Published:December 16, 2021DOI:



      Considerable numbers of patients with metastatic urothelial carcinoma (mUC) develop bone metastases (BoM). Their impact on the efficacy of immune-checkpoint inhibitors (ICIs) is not yet investigated.


      Between July 2014 and August 2020 data on pts treated with single-agent ICIs after failure of at least 1 previous line of chemotherapy for advanced disease, were retrospectively collected across 14 Italian centers. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method. Cox regression analysis was performed evaluating potential prognostic factors for OS and PFS. Each factor was evaluated in univariable (UVA) and multivariable analysis (MVA).


      A total of 208 evaluable patients treated with ICIs were identified, including 122 (59%) without BoM (BoM-) and 86 (41%) with bone metastases (BoM+). After a median follow-up of 22.3 months, BoM+ patients showed shorter OS (median 3.9 vs 7.8 months, HR 1.59 [95%CI, 1.15-2.20], P = .005) and shorter PFS (median 2.0 vs 2.6 months, HR 1.76 [95%CI, 1.31-2.37], P < .001). Probability of being alive was 62% vs 40% after 6 months, 38% vs 23% after 1 year and 24% vs 13% after 2 years, in BoM- and BoM+ respectively. Within each Bellmunt score, OS and PFS of BoM+ patients were shorter. Both presence of BoM and higher Bellmunt risk score were significantly associated with shorter OS and PFS in UVA and MVA.


      Patients treated with single-agent ICIs for BoM+ mUC have a dismal prognosis compared to BoM-. Further research is needed to understand the mechanism behind these outcomes.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Shinagare AB
        • Ramaiya NH
        • Jagannathan JP
        • et al.
        Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor.
        AJR Am J Roentgenol. 2011; 196: 117-122
        • Sengelov L
        • Kamby C
        • von der Maase H
        Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma.
        J Urol. 1996; 155: 111-114
        • Necchi A
        • Pond GR
        • Pal SK
        • et al.
        Bone metastases as the only metastatic site in patients with urothelial carcinoma: focus on a special patient population.
        Clin Genitourin Cancer. 2018; 16: e483-e490
        • Owari T
        Clinical features and risk factors of skeletal-related events in genitourinary cancer patients with bone metastasis: a retrospective analysis of prostate cancer, renal cell carcinoma, and urothelial carcinoma.
        Oncology. 2018; 95 (Epub 2018 Jun 6): 170-178
        • Tsuda Y
        • Nakagawa T
        • Homma Y
        • et al.
        Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis.
        Int J Clin Oncol. 2017; 22: 533-548
        • Patel SH
        • Panian J
        • Bree K
        • Derweesh I
        • Millard F
        • Randall J
        • Mckay R
        Systemic Treatment of Bone Disease in Metastatic Urinary Malignancies.
        Eur Urol Focus. 2020; 6 (Epub 2019 Jun 27): 17-25
        • Svensson E
        • Christiansen CF
        • Ulrichsen SP
        • Rørth MR
        • Sørensen HT.
        Survival after bone metastasis by primary cancer type: a Danish population-based cohort study.
        BMJ Open. 2017; 7 (bmjopen-2017-016022)e016022
        • Powles T
        • Eder JP
        • Fine GD
        • et al.
        MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
        Nature. 2014; 515: 558-562
        • Rosenberg JE
        • Hoffman-Censits J
        • Powles T
        • et al.
        Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
        Lancet. 2016; 387: 1909-1920
        • Bellmunt J
        • de Wit R
        • Vaughn DJ
        • et al.
        Pembrolizumab as second line therapy for advanced urothelial carcinoma.
        N Engl J Med. 2017; 376: 1015-1026
        • Powles T
        • Duran I
        • van der Heijden MS
        • et al.
        Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, openlabel, phase 3 randomised controlled trial.
        Lancet. 2018; 391: 748-757
        • Sharma P
        • Retz M
        • Siefker-Radtke A
        • et al.
        Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
        Lancet Oncol. 2017; 18: 312-322
        • Massard C
        • Gordon MS
        • Sharma S
        • et al.
        Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand- 1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer.
        J Clin Oncol. 2016; 34: 3119-3125
        • Balar AV
        • Castellano D
        • O'Donnell PH
        • et al.
        First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
        Lancet Oncol. 2017; 18: 1483-1492
        • Balar AV
        • Galsky MD
        • Rosenberg JE
        • et al.
        Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
        Lancet. 2017; 389: 67-76
        • Gourd E.
        EMA restricts use of anti-PD-1 drugs for bladder cancer.
        Lancet Oncol. 2018; 19: e341
        • FDA
        FDA alerts health care professionals and oncology clinical investigators about an efficacy issue identified in clinical trials for some patients taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as monotherapy totreat urothelial cancer with lowexpression of PD-L1. 2018;
        • Powles T
        • Park SH
        • Voog E
        • et al.
        Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma.
        N Engl J Med. 2020; 383 (NEJMoa2002788Epub 2020 Sep 18): 1218-1230
        • Gomez de Liano Lista Alfonso
        Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer.
        Eur Urol. 2019;
        • Schemper M
        • Smith TL.
        A note on quantifying follow-up in studies of failure time.
        Control Clin Trials. 1996; 17: 343-346
        • Bellmunt J
        • Choueiri TK
        • Fougeray R
        • et al.
        Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.
        J Clin Oncol. 2010; 28 (Epub 2010 Mar 15): 1850-1855
        • Raggi D
        • Miceli R
        • Sonpavde G
        • et al.
        Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.
        Ann Oncol. 2016; 27: 49-61
        • Ramos JD
        • Cheng HH
        • Yu EY.
        Long-term survival in bone-predominant metastatic urothelial carcinoma.
        Clin Genitourin Cancer. 2014; 12: e241-e244
        • Fradet Y
        • Bellmunt J
        • Vaughn DJ
        • et al.
        Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
        Ann Oncol. 2019; 30: 970-976
        • Landi L
        • D’Incà F
        • Gelibter A
        • et al.
        Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer.
        J immunother cancer. 2019; 7: 316
        • Mohme M
        • Riethdorf S
        • Pantel K.
        Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape.
        Nat Rev Clin Oncol. 2017; : 155-167
        • Jiao S
        • Subudhi SK
        • Aparicio A
        • et al.
        Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy.
        Cell. 2019; 179 (e13): 1177-1190
        • Xiang L
        • Gilkes DM.
        The contribution of the immune system in bone metastasis pathogenesis- int.
        J Mol Sci. 2019; 20: 999
        • Mariathasan S
        • Turley SJ
        • Nickles D
        • et al.
        TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
        Nature. 2018; 554 (Epub 2018 Feb 14): 544-548
        • Apolo AB
        • Nadal R
        • Tomita Y
        • et al.
        Cabozantinib in patients with platinum refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
        Lancet Oncol. 2020; 21: 1099-1109
        • Marandino L
        • Raggi D
        • Giannatempo P
        • et al.
        Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy: Safety and preliminary activity of the open-label, single-arm, phase II ARCADIA trial.
        Ann Oncol. 2020; 31 (SUPPLEMENT): S595
        • Fioramonti M
        • Santini D
        • Iuliani M
        • et al.
        Pantano F.Oncotarget. 2017; 8: 20113-20121